By Giulia Petroni

Roche Holding AG on Wednesday said that a phase 3 study of tiragolumab for the treatment of extensive stage small-cell lung cancer failed to meet its co-primary endpoint.

The Swiss pharmaceutical company said the study was evaluating the use of tiragolumab plus tecentriq and chemotherapy.

"The co-primary endpoint of overall survival wasn't met at its interim analysis and is unlikely to reach statistical significance at the planned final analysis," it said.

Data will be presented at an upcoming medical meeting, according to Roche.

Write to Giulia Petroni at giulia.petroni@wsj.com

(END) Dow Jones Newswires

March 30, 2022 01:32 ET (05:32 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Roche (QX) Charts.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Roche (QX) Charts.